Mostrar el registro sencillo del ítem
dc.contributor.author | Correale, Jorge | |
dc.contributor.author | Abad, Patricio | |
dc.contributor.author | Alvarenga, Regina | |
dc.contributor.author | Alves-Leon, Soniza | |
dc.contributor.author | Armas, Elizabeth | |
dc.contributor.author | Barahona, Jorge | |
dc.contributor.author | Buzo, Ricardo | |
dc.contributor.author | Corona, Teresa | |
dc.contributor.author | Cristiano, Edgardo | |
dc.contributor.author | Gracia, Fernando | |
dc.contributor.author | Bonitto, Juan Garcia | |
dc.contributor.author | Macias, Miguel Angel | |
dc.contributor.author | Soto, Arnoldo | |
dc.contributor.author | Vizcarra-Escobar, Darwin | |
dc.contributor.author | Freedman, Mark S. | |
dc.date.accessioned | 2020-06-10T18:12:13Z | |
dc.date.available | 2020-06-10T18:12:13Z | |
dc.date.issued | 2014 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12866/8057 | |
dc.description.abstract | The Latin American MS Experts' Forum has developed practical recommendations on the initiation and optimization of disease-modifying therapies in patients with relapsing–remitting multiple sclerosis (RRMS). The recommendations reflect the unique epidemiology of MS and the clinical practice environment in Latin American countries. Treatment response may be evaluated according to changes in relapses; progression, as assessed by the Expanded Disability Status Scale and the Timed 25-foot Walk; and lesion number on magnetic resonance imaging. Follow-up assessments are recommended every six months, or annually for stable patients. Cognitive function should be evaluated in all RRMS patients at baseline and annually thereafter. These recommendations are intended to assist clinicians in Latin America in developing a rational approach to treatment selection and sequencing for their RRMS patients. | en_US |
dc.language.iso | eng | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Journal of the Neurological Sciences | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | |
dc.subject | Disease Management | en_US |
dc.subject | Algorithm | en_US |
dc.subject | Clinical recommendations | en_US |
dc.subject | Disability | en_US |
dc.subject | Humans | en_US |
dc.subject | Immunosuppressive Agents/therapeutic use | en_US |
dc.subject | Interferon-beta/therapeutic use | en_US |
dc.subject | Latin America | en_US |
dc.subject | Latin America/epidemiology | en_US |
dc.subject | Mitoxantrone/therapeutic use | en_US |
dc.subject | MRI | en_US |
dc.subject | Multiple sclerosis | en_US |
dc.subject | Multiple Sclerosis, Relapsing-Remitting/diagnosis/epidemiology/therapy | en_US |
dc.subject | Practice Guidelines as Topic/standards | en_US |
dc.subject | Relapses | en_US |
dc.subject | Treatment | en_US |
dc.subject | Treatment Outcome | en_US |
dc.subject | Vitamin D/therapeutic use | en_US |
dc.title | Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization | en_US |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | https://doi.org/10.1016/j.jns.2014.02.017 | |
dc.subject.ocde | https://purl.org/pe-repo/ocde/ford#3.02.25 | |
dc.relation.issn | 1878-5883 |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |